<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[formulation Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/formulation.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to formulation]]></description>
	<s:counts start="0" returned="20" found="250" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Programmer, Engineering & Scientific]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=322760]]></link>
		<description><![CDATA[The Programmer, Engineering & Scientific job description template includes the following job summary: Convert problem formulations into a formats that can be processed by a computer, resolve symbolic formulations and prepare flow charts and block diagrams. Enter programs into computer systems and resolve problems of intent, inaccuracy, or feasibility of...]]></description>
		<s:doctype><![CDATA[Tools & templates]]></s:doctype>
		<pubDate>Sun, 01 Nov 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/business+%2526+legal+reports+inc..html"><![CDATA[Business & Legal Reports Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/programmer.html"><![CDATA[Programmer]]></category>
		<category domain="http://resources.bnet.com/topic/computer.html"><![CDATA[Computer]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[Productivity]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
	</item>
	<item>
		<title><![CDATA[SuperGen, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-356939.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions Your first question comes from Joe Pantginis - Merriman Curhan Ford & Co. Joe Pantginis - Merriman Curhan Ford & Co. A couple of quick questions if you don't mind, first on GSK. With regard to the milestones, I know you can't disclose...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 26 Oct 2009 18:05:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/supergen+inc..html"><![CDATA[SuperGen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/databases.html"><![CDATA[Databases]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/data+management.html"><![CDATA[Data Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SUPG</category>
		<category domain="tickers">SUPG</category>
	</item>
	<item>
		<title><![CDATA[SuperGen, Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-274757.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instruction Your first question comes from the line of Elemer Piros - Rodman & Renshaw LLC. Elemer Piros - Rodman & Renshaw LLC What a relief to be in such a strong financial position. James Manuso It is remarkable, but planned. Elemer Piros - Rodman...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 02 Mar 2009 19:29:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/data.html"><![CDATA[Data]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/conference.html"><![CDATA[Conference]]></category>
		<category domain="http://resources.bnet.com/topic/supergen+inc..html"><![CDATA[SuperGen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SUPG</category>
		<category domain="tickers">SUPG</category>
	</item>
	<item>
		<title><![CDATA[Alnylam Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-272712.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator (Operator's instruction) Your first question comes from the line of Sapna Srivastava - Morgan Stanley. Analyst for Sapna Srivastava - Morgan Stanley It is Dave calling in for Sapna. Just a question on delivery, I know that is sort of an ongoing topic for everyone in the...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 24 Feb 2009 20:57:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/delivery.html"><![CDATA[Delivery]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[Cell]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
	<item>
		<title><![CDATA[GSK Receives Complete Response Letter for "Undisclosed" Yucky Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000538/gsk-receives-complete-response-letter-for-undisclosed-drug/]]></link>
		<description><![CDATA[GlaxoSmithKline and drug development partner Eurand have received a "complete response letter" from the FDA for a mystery compound -- EUR-1048. GSK and Eurand have both declined to reveal what EUR-1048 is for.    Eurand's statement says:  EUR-1048 is an orally disintegrating tablet ODT formulation with an...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sun, 28 Dec 2008 15:09:23 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/eurand.html"><![CDATA[Eurand]]></category>
		<category domain="http://resources.bnet.com/topic/eur-1048.html"><![CDATA[EUR-1048]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Columbia Laboratories, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-250405.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions We will now take our first question from Tom Shrader with Rodman & Renshaw. Tom Shrader &#8211; Rodman & Renshaw  Good morning. Robert Mills Good morning, Tom. Tom Shrader &#8211; Rodman & Renshaw  Congratulations on all the ASRM presence. I have three kind...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 18 Nov 2008 23:01:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/data.html"><![CDATA[Data]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/polymer.html"><![CDATA[Polymer]]></category>
		<category domain="http://resources.bnet.com/topic/columbia+laboratories+inc..html"><![CDATA[Columbia Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/data.html"><![CDATA[Data]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/polymer.html"><![CDATA[Polymer]]></category>
		<category domain="http://resources.bnet.com/topic/columbia+laboratories+inc..html"><![CDATA[Columbia Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CBRX</category>
		<category domain="tickers">CBRX</category>
	</item>
	<item>
		<title><![CDATA[Santarus, Inc. (F3Q08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-246215.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Ladies and gentlemen Operator Instruction Gerald Proehl While we are waiting for questions, I would like to inform you that we will be presenting at the Rodman & Renshaw Tenth Annual Healthcare Conference, taking place at the New York Palace Hotel on November 12, at 9:55am eastern...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 03 Nov 2008 19:24:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/ubs+ag.html"><![CDATA[UBS AG]]></category>
		<category domain="http://resources.bnet.com/topic/santarus+inc..html"><![CDATA[Santarus Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks.html"><![CDATA[Notebooks]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks+%2526+tablets.html"><![CDATA[Notebooks & Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/ubs+ag.html"><![CDATA[UBS AG]]></category>
		<category domain="http://resources.bnet.com/topic/santarus+inc..html"><![CDATA[Santarus Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks.html"><![CDATA[Notebooks]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks+%2526+tablets.html"><![CDATA[Notebooks & Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UBS</category>
		<category domain="tickers">UBS</category>
	</item>
	<item>
		<title><![CDATA[Legal Opinions - U.S. District Court, Maryland: October 20, 2008]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4183/is_20081020/ai_n30924945]]></link>
		<description><![CDATA[U.S. DISTRICT COURT, MARYLAND   Contracts   Scope of agency relationship   BOTTOM LINE: The employment of an agent for purposes of issuing title insurance does not, by itself, establish an agency relationship for purposes of settlement and closing activities undertaken by the title agent.  ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 20 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agency.html"><![CDATA[agency]]></category>
		<category domain="http://resources.bnet.com/topic/agent.html"><![CDATA[agent]]></category>
		<category domain="http://resources.bnet.com/topic/cir.html"><![CDATA[Cir]]></category>
		<category domain="http://resources.bnet.com/topic/construction.html"><![CDATA[construction]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/specification.html"><![CDATA[specification]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+district+court.html"><![CDATA[U.S. District Court]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Cytokinetics Announces Interim Clinical Trial Data Relating to CK-1827452 Presented at the European Society of Cardiology Congress 2008]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200809/ai_n28053736]]></link>
		<description><![CDATA[Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an ongoing Phase IIa clinical trial of CK-1827452 were presented as a poster presentation at the European Society of Cardiology ESC Congress 2008, at the Messe München GmbH in Munich, Germany.  The trial is evaluating an intravenous formulation...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 02 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cohort.html"><![CDATA[cohort]]></category>
		<category domain="http://resources.bnet.com/topic/cytokinetics.html"><![CDATA[Cytokinetics]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTK</category>
		<category domain="tickers">CYTK</category>
	</item>
	<item>
		<title><![CDATA[Formulations at Lonza achieve EPA registration]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb3042/is_9_45/ai_n28567819]]></link>
		<description><![CDATA[Lonza received U.S. Environmental Protection Agency EPA registration for several formulations to effectively inactivate H5N1 "bird flu" virus that has spread across Asia and Europe.  The company's formulations--used to clean, sanitize and disinfect hard non-porous surfaces--were shown to inactivate the virus, precluding its spread.  More info: www.lonza.com]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 01 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+environmental+protection+agency.html"><![CDATA[U.S. Environmental Protection Agency]]></category>
	</item>
	<item>
		<title><![CDATA[Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject&#153; at the 12th World Congress on Pain]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_21/ai_n28024848]]></link>
		<description><![CDATA[GLASGOW, Scotland -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal Phase 3 study of Dyloject([TM]). At the 12th World Congress on Pain, held in Glasgow, Scotland. Dyloject was launched in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/glasgow.html"><![CDATA[Glasgow]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/scotland.html"><![CDATA[Scotland]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_19/ai_n28010676]]></link>
		<description><![CDATA[- Novel Cationic Peptides from University of Michigan improve siRNA delivery -  BOTHELL, Wash. -- MDRNA, Inc. (Nasdaq: MRNA) announced today that it has signed an exclusive license agreement to intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids. Terms of the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 19 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+michigan.html"><![CDATA[University of Michigan]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_19/ai_n28010784]]></link>
		<description><![CDATA[GLASGOW, Scotland -- Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY([R]), an investigational drug to treat chronic pain. The final data confirm REMOXY provides effective around-the-clock analgesia within a patented formulation...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 19 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alcohol.html"><![CDATA[alcohol]]></category>
		<category domain="http://resources.bnet.com/topic/companies.html"><![CDATA[Companies]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/scotland.html"><![CDATA[Scotland]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[Santarus Announces Issuance Date of Additional U.S. Patent Covering Zegerid Products]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_July_8/ai_n27892272]]></link>
		<description><![CDATA[Notice of Allowance previously announced in April 2008  SAN DIEGO -- Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office USPTO indicating that U.S. patent application number 10/641,732 will issue...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 08 Jul 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/issuance.html"><![CDATA[issuance]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent and Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Techalt, Inc. Announces Petition for Revival of the Patent Application for Stan's Rodeo Ointment]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_5/ai_n25486897]]></link>
		<description><![CDATA[SEATTLE -- Techalt, Inc. (Pink Sheets:TCLT) ("Techalt" or "Company") announced that the petition for revival of the patent application filed with the US Patent and Trademark Office ("USPTO"), covering the formulations and processing of Stan's Rodeo Ointment ("SRO"), has been submitted and received by the USPTO following the unintentional abandonment...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/petition.html"><![CDATA[petition]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent and Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Skyepharma PLC - Interim Management Statement]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200805/ai_n25442704]]></link>
		<description><![CDATA[FOR IMMEDIATE RELEASE   SKYEPHARMA PLC -  Q1 2008 INTERIM MANAGEMENT STATEMENT   LONDON, UK, 19 May 2008 - SkyePharma PLC (LSE: SKP) today makes its first Interim Management Statement ("IMS").   Highlights of the first quarter    - Revenues in the first quarter...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 19 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[sales]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Pesticides: back to basics]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0ZQQ/is_4_56/ai_n25409294]]></link>
		<description><![CDATA[The following PowerPoint review of pesticides was presented at the Mushroom Central and L.F. Lambert Spawn Co. pesticide meeting in February. The presentation explains the various types of pest control, registration requirements, label components, worker protection language and formulations.  (1) Back to Basics--EPA  * The Environmental Protection Agency...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+environmental+protection+agency.html"><![CDATA[U.S. Environmental Protection Agency]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[OCLC Programs and Research and the Association for Library and Information Science Education.(noted & quoted: people * libraries * awards * promotions)(Online Computer Library Center Inc.)(Brief article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6365/is_200804/ai_n26664684]]></link>
		<description><![CDATA[Youngok Choi, Ph.D., of the School of Library and Information  Science at the Catholic University of America (Washington, D.C.), will  investigate undergraduates' image-searching processes on the web in  the case study, "Analyzing Image Searching on the Web: How Do  Undergraduates Search and Use Visual Information?" ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+north+carolina.html"><![CDATA[University of North Carolina]]></category>
		<category domain="http://resources.bnet.com/topic/web.html"><![CDATA[Web]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ACTC, AFPC, EDNE, MMAM, MMGP, OGOH Have Also Been Added To Naked Short List Today.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200803/ai_n25268372]]></link>
		<description><![CDATA[M2 PRESSWIRE-27 March 2008-BUYINS.NET: ACTC, AFPC, EDNE, MMAM,  MMGP, OGOH Have Also Been Added To Naked Short List TodayC1994-2008 M2  COMMUNICATIONS LTD    RDATE:27032008    BUYINS.NET, www.buyins.net, announced today that these select  companies have been added to the NASDAQ, AMEX and NYSE naked...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 27 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/database.html"><![CDATA[database]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/stem-cell.html"><![CDATA[stem-cell]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
	</item>
	<item>
		<title><![CDATA[Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200803/ai_n25296972]]></link>
		<description><![CDATA[NOVATO, California, March 19 /PRNewswire/ --     - Acquires Rights from UCSD to Develop Cysteamine for the Treatment  of  NASH     - Enters ConviviaTM Formulation and Manufacturing Agreement with  Patheon Pharmaceuticals     Raptor Pharmaceuticals Corp. ("Raptor" or the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/raptor+pharmaceuticals+corp..html"><![CDATA[Raptor Pharmaceuticals Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RPTP</category>
		<category domain="tickers">RPTP</category>
	</item>
</channel>
</rss>
